Penwest Pharmaceuticals Co.(fka PPCO)

[surf1944]

8:57AM Penwest Pharma announces results of phase IIa clinical study of Nalbuphine ER; intends to advance Nalbuphine ER into phase IIb (PPCO) 5.30 : Co reported results from the Co's Phase IIa clinical trial evaluating nalbuphine hydrochloride extended release tablets (nalbuphine ER), a product Penwest is developing for the treatment of moderate chronic pain. The Company has concluded that the results of this study showed efficacy sufficient to support its continued development of the drug, and it plans to conduct a Phase IIb trial commencing in the second half of this year. (Stock is halted)